Global Alert and Response (GAR)

Hepatitis C

Reference List

  1. Churchill's Illustrated Medical Dictionary. New York, Churchill Livingstone, 1989.
  2. Stedman's Medical Dictionary, 26th ed. Baltimore, Williams & Wilkins, 1995.
  3. Proceedings of the International Workshop on Epidemiology, Diagnosis and Management of Hepatitis C Infection. Medicine and the Community, 1996, 6-7:1-32.
  4. Cite des Sciences et de l'Industrie--La Villette--Paris. Conférence de consensus Traitement de l'hépatite C. Paris, 16-17 January. Cite des Sciences et de l'Industrie--La Villette--Paris. Ann Chir, 1997:212-216.
  5. EASL International Consensus Conference on Hepatitis C. Consensus Statement. Journal of Hepatology, 1999, 31:3-8.
  6. Dorland's Illustrated Medical Dictionary, 29th ed. Philadelphia, WB Saunders Co., 2000.
  7. Abrignani S, Houghton M, Hsu HH. Perspectives for a vaccine against hepatitis C virus. Journal of Hepatology, 1999, 31:259-263.
  8. Adinolfi L et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology, 2001, 33:1358-1364.
  9. Alberti A et al. Therapy of acute hepatitis C. Hepatology, 2003, 36:S195-S200.
  10. Alter MJ. Epidemiology of hepatitis C. Hepatology, 1997, 26:62S-65S.
  11. Alter MJ. Hepatitis C virus infection in the United States. Journal of Hepatology, 1999, 31:88-91.
  12. Ansar MM, Kooloobandi A. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. Journal of Viral Hepatology, 2002, 9:390-392.
  13. Barnes E et al. Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin. Journal of Hepatology, 1999, 31:244-249.
  14. Bonino F et al. Impact of interferon-alpha therapy on the development of hepatocellular carcinoma in patients with liver cirrhosis: results of an international survey. Journal of Viral Hepatology, 1997, 4:79-82.
  15. Bukh J et al. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. Copenhagen Dialysis HCV Study Group. J Infect Dis, 1993, 168:1343-1348.
  16. Buti M, Estaban R. Retreatment of interferon relapse patients with chronic hepatitis C. Journal of Hepatology, 1999, 31:174-177.
  17. Centers for Disease Control and Prevention. Hepatitis C virus and disease, 1999.
  18. Chang KM. Immunopathogenesis of hepatitis C virus infection. Clinical Liver Disease, 2003, 7:89-105.
  19. Choo Q-L et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 1989, 244:359-364.
  20. Civeira M-P, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. Journal of Hepatology, 1999, 31:237-243.
  21. Colombo M. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. Journal of Hepatology, 1999, 31:25-30.
  22. Colombo M, Sangiovanni A. The European approach to hepatocellular carcinoma. Hepatogastroenterology, 2002, 49:12-16.
  23. De Francesco R. Molecular virology of the hepatitis C virus. Journal of Hepatology, 1999, 31:47-53.
  24. Degos F. Hepatitis C and alcohol. Journal of Hepatology, 1999, 31:113-118.
  25. Dienes HP, Drebber U, von Both I. Liver biopsy in hepatitis C. Journal of Hepatology, 1999, 31:43-46.
  26. Dore G. HIV and hepatitis C coinfection. Proceedings of 10th Australasian Society for HIV Medicine Conference. 1998,
  27. Fan ST, Cheung ST, Lo CM. Indications for liver transplantation in patients with chronic hepatitis B and C virus infection and hepatocellular carcinoma. J Gastroenterol Hepatol, 2000, 15:181-186.
  28. Fang CT et al. Fluctuation of HCV viral load before seroconversion in a healthy volunteer blood donor. Transfusion, 2003, 43:541-544.
  29. Ferrari C et al. Immunopathogenesis of hepatitis C virus infection. Journal of Hepatology, 1999, 31:31-38.
  30. Foy E et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science, 2003, 300:1145-1148.
  31. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Seminars in Liver Disease, 1995, 15:82-91.
  32. Frilling A, Malago M, Broelsch CE. Current status of liver transplantation for treatment of hepatocellular carcinoma. Dig Dis, 2001, 19:333-337.
  33. Fujimura Y et al. Genotypes and multiple infections with hepatitis C virus in patients with haemophilia A in Japan. Journal of Viral Hepatology, 1996, 3:79-84.
  34. Gerlach JT et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology, 2003, 125:80-88.
  35. Harris DR, Gonin R, Alter HJ. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med, 2001, 134:124.
  36. Herrera JL. Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who failed to respond to interferon therapy. American Journal of Gastroenterology, 1999, 94:3571-3575.
  37. Hickman IJ, Clouston AD, Macdonald GA. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut, 2002, 51:89-94.
  38. Hoofnagle JH. Management of hepatitis C: current and future perspectives. Journal of Hepatology, 1999, 31:264-268.
  39. Houghton M. Hepatitis C viruses. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology, 3rd ed. Philadelphia, Lippincott - Raven, 1996:1035-1058.
  40. Hourigan L, Macdonald G, Purdie D. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology, 1999, 29:1215-1219.
  41. Hsu HH, Greenberg HB. Hepatitis C. In: Hoeprich PD, Jordan MC, Ronald AR, eds. Infectious Diseases. A treatise of infectious processes., 5th ed. JB Lippincott Co, Philadelphia, 1994:820-825.
  42. Huraib S et al. High prevalence of and risk factors for hepatitis C in haemodialysis patients in Saudi Arabia: a need for new dialysis strategies. Nephrol Dial Transplant, 1995, 10:470-474.
  43. Jaeckel E et al. Treatment of acute hepatitis C with interferon alfa-2b. New England Journal of Medicine, 2001, 345:1452-1457.
  44. Jubin R et al. Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation. Journal of Infectious Diseases, 2000, 181:331-334.
  45. Kane A et al. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ, 1999, 77:801-807.
  46. Kim WR. The burden of hepatitis C in the United States. Hepatology, 2002, 36:S30-S34.
  47. Klenerman P et al. Immunity to hepatitis C virus: stunned but not defeated. Microbes Infect, 2002, 4:57-65.
  48. Kuo G et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science, 1989, 244:362-364.
  49. Lavanchy D, McMahon B. Worldwide prevalence and prevention of hepatitis C. In: Liang TJ, Hoofnagle JH, eds. Hepatitis C. San Diego, Academic Press, 2000:185-202.
  50. Lavezzo B, Rizzetto M. Treatment of recurrent hepatitis C virus infection after liver transplantation. Journal of Hepatology, 1999, 31:222-226.
  51. Lee SR et al. Efficacy of a hepatitis C virus core antigen enzyme-linked immunosorbent assay for the identification of 'window-phase' blood donations. Vox Sanguinis, 2001, 80:19-23.
  52. Lemon SM, Brown EA. Hepatitis C virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principle and Practice of Infectious Disease, Fourth. New York, Churchill Livingstone, 1995:1474-1486.
  53. Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. Journal of Hepatology, 1999, 31:39-42.
  54. Mansour-Ghanaei F et al. Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran). Med Sci Monit, 2002, 8:CR797-800.
  55. Marcellin P. Hepatitis C: the clinical spectrum of the disease. Journal of Hepatology, 1999, 31:9-16.
  56. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine, 1999, 17:1730-1733.
  57. Memon MI, Memon MA. Hepatitis C: an epidemiological review. Journal of Viral Hepatology, 2002, 9:84-100.
  58. Mondelli MU, Silini E. Clinical significance of hepatitis C virus genotypes. Journal of Hepatology, 1999, 31:65-70.
  59. Morikawa T et al. Prevalence and characterization of hepatitis C virus in hemodialysis patients. Intern Med, 1999, 38:626-631.
  60. Morin T, Pariente A. Hepatites aigues C: etude retrospective de 62 cas. Gastroenterol Clin Biol, 2002, 26:994-1000.
  61. Moya A et al. Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C? Liver Transpl, 2002, 8:1020-1027.
  62. Muerhoff AS et al. Detection of HCV core antigen in human serum and plasma with an automated chemiluminescent immunoassay. Transfusion, 2002, 42:349-356.
  63. Nakamoto Y et al. Analysis of the CD8-positive T cell response in Japanese patients with chronic hepatitis C using HLA-A*2402 peptide tetramers. Journal of Medical Virology, 2003, 70:51-61.
  64. Nascimbeni M et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. Journal of Virology, 2003, 77:4781-4793.
  65. National Institutes of Health. Consensus Development Conference Statement: Management of Hepatitis C: 2002, June 10-12. 2002,
  66. Nomiyama K et al. Prevalence of hepatitis C virus antibody in patients on chronic hemodialysis. Fukuoka Igaku Zasshi, 1998, 89:232-237.
  67. Nubling CM et al. Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion, 2002, 42:1037-1045.
  68. Ohno T, Lau JYN. The "gold-standard," accuracy, the current concepts:hepatitis C virus genotypes and viremia. Hepatology, 1996, 24:1312-1315.
  69. Pawlotsky J-M. Diagnostic tests for hepatitis C. Journal of Hepatology, 1999, 31:71-79.
  70. Powell EEHow host and viral factors affect fibrosis progression in HCV. 3rd Australasian Conference on Hepatitis C.Melbourne2002
  71. Poynard T et al. Effects of interferon therapy in "non responder"patients with chronic hepatitis C. Journal of Hepatology, 1999, 31:178-183.
  72. Poynard T et al. Interferon for acute hepatitis C. 2002, Cochrane Database Syst Rev CD000369
  73. Prince AM, Shata MT. Immunoprophylaxis of hepatitis C virus infection. Clinical Liver Disease, 2001, 5:1091-1103.
  74. Purcell RH. Hepatitis C virus. In: Webster RG, Granoff A, eds. Encyclopedia of Virology. London, Academic Press Ltd, 1994:569-574.
  75. Roayaie S et al. Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience. Ann Surg Oncol, 2000, 7:764-770.
  76. Roy K et al. Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect, 2002, 129:585.
  77. Ruiz-Moreno M, Leal-Orozco A, Millàn A. Hepatitis C virus infection in children. Journal of Hepatology, 1999, 31:124-129.
  78. Saldanha J, Lelie N, Heath A. Establishment of the First International Standard for Nucleic Acid Amplification Technology (NAT) Assays for HCV RNA. Vox Sanguinis, 1998, 76:149-158.
  79. Samuel D, Feray C. Recurrence of hepatitis C virus infection after liver transplantation. Journal of Hepatology, 1999, 31:217-221.
  80. Sanchez-Quijano A, Andreu J, Gavilan F. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis, 1995, 14:949-953.
  81. Saxena AK et al. Impact of dedicated space, dialysis equipment, and nursing staff on the transmission of hepatitis C virus in a hemodialysis unit of the middle east. Am J Infect Control, 31: 26-33. Am J Infect Control, 2003, 31:26-33.
  82. Schalm SW et al. New treatment strategies in non-responder patients with chronic hepatitis C. Journal of Hepatology, 1999, 31:184-188.
  83. Schneeberger PM et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis, 2000, 182:1291-1299.
  84. Schreiber GB et al. The risk of transfusion-transmitted viral infections. New England Journal of Medicine, 1996, 334:1685-1690.
  85. Schulman S, Grillner L. Antibodies against hepatitis C in a population of Swedish haemophiliacs and heterosexual partners. Scandinavian Journal of Infectious Diseases, 1990, 22:393-397.
  86. Schuttler CG et al. Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. Lancet, 2000, 355:41-42.
  87. Schvarcz R et al. Nosocomial transmission of hepatitis C virus. Infection, 1997, 25:74-77.
  88. Shata MT et al. Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. Journal of Viral Hepatology, 2002, 9:400-410.
  89. Simmonds P. Viral heterogeneity of the hepatitis C virus. Journal of Hepatology, 1999, 31:54-60.
  90. Tassopoulos NC. Treatment of patients with chronic hepatitis C and normal ALT levels. Journal of Hepatology, 1999, 31:193-196.
  91. Thomson M et al. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. Journal of Virology, 2003, 77:862-870.
  92. Tosti ME et al. An estimate of the current risk of transmitting blood-borne infections through blood transfusion in Italy. British Journal of Haematology, 2002, 117:215-219.
  93. Urdea MS et al. Hepatitis C - diagnosis and monitoring. Clinical Chemistry, 1997, 43:1507-1511.
  94. US Department of Health and Human Services.Centers for Disease Control and Prevention. Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. Morbidity and Mortality Weekly Report, 1998, 47.
  95. van der Poel CL. Hepatitis C virus and blood transfusion: past and present risks. Journal of Hepatology, 1999, 31:101-106.
  96. Viral Hepatitis Prevention Board. Hepatitis A, B & C: defining workers at risk. Viral Hepatitis, 1995, 3.
  97. Walker CM. Hepatitis C virus. In: Ahmed R, Chen I, eds. Persistent Viral Infections. Chichester, Wiley, 1999:93-115.
  98. Wejstål R. Sexual transmission of hepatitis C virus. Journal of Hepatology, 1999, 31:92-95.
  99. Wiley TE et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology, 1998, 28:805-809.
  100. World Health Organization. Hepatitis C. Weekly Epidemiological Record, 1997, 72:65-69.
  101. World Health Organization. Hepatitis C, 1997,, World Health Organization,
  102. World Health Organization. Hepatitis C - global prevalence. Weekly Epidemiological Record, 1997, 72:341-344.
  103. World Health Organization. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in Collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. Journal of Viral Hepatology, 1999, 6:35-47.
  104. World Health Organization. Hepatitis C - global prevalence (update). Weekly Epidemiological Record, 1999, 74:425-427.
  105. Yee TT et al. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut, 2000, 47:851.
  106. Zanetti AR, Tanzi E, Newell ML. Mother-to-infant transmission of hepatitis C virus. Journal of Hepatology, 1999, 31:96-100.